Press Releases

Jeddah, Saudi Arabia--(Newsfile Corp. - May 6, 2024) - Mohammad Bahareth Consultancy & Research Office proudly announces that its founder, Mohammad Bahareth, has been honored as "Business Consultant of the Year 2023" by the Prestige Awards Middle East.

Mohammad Bahareth

The Prestige Awards recognize excellence in delivering high-quality products and services. Judges look for innovation, value, ethical practices, and consistent performance in their selections. Winners are... (continue reading...)

JERSEY CITY, N.J., May 6, 2024 /PRNewswire/ -- The destination dispensary for cannabis connoisseurs has opened its doors in The Heights Jersey City. Blossom Dispensary, located at 746 Tonnelle Avenue, with easy access to Routes 1 & 9 opened on April 19th, 2024, marking a significant milestone in New Jersey's growing cannabis market. Just 15 minutes from New York City, the American Dream Mall, and MetLife Stadium and conveniently situated in between the Lincoln Tunnel... (continue reading...)

Paris, May 06, 2024 (GLOBE NEWSWIRE) -- According to International Relations Study Association(IRSA), Chinese President Xi Jinping landed in Paris in the afternoon of May 5th, marking his first overseas visit of the year. In this important year of the 75th anniversary of the founding of the People's Republic of China, the first overseas visit of a Chinese head of state has even more special significance.

This is Chinese President Xi Jinping’s third state visit... (continue reading...)

ASHEVILLE, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- SECU Foundation has awarded $250,000 to MemoryCare for the programmatic expansion of dementia care and in-home clinical and care management services in rural Western North Carolina. The expansion at its Haywood County site will provide support for an additional 130 individuals living with Alzheimer’s and other cognitive impairments, along with 300 caregivers, on an annual basis.

This grant follows two previous... (continue reading...)

Treatment with abelacimab could result in potential cost-savings of $50,000 over a lifetime per patient basis and higher quality-adjusted life years in atrial fibrillation patients at a high risk of stroke versus rivaroxaban

Cost-effectiveness analysis based upon the results from the landmark AZALEA-TIMI 71 study which was stopped early by the Data Monitoring Committee (DMC) due to a substantially greater than anticipated reduction in major and clinically relevant... (continue reading...)